Wright AA, Zhang B, Keating NL, Weeks JC, Prigerson HG. Associations between palliative chemotherapy and adult cancer patients’ end of life care and place of death: prospective cohort study. BMJ. 2014;348:g1219.

Article  PubMed  PubMed Central  Google Scholar 

Earle CC, Park ER, Lai B, Weeks JC, Ayanian JZ, Block S. Identifying potential indicators of the quality of end-of-life cancer care from administrative data. J Clin Oncol. 2003;21:1133–8.

Article  PubMed  Google Scholar 

Dunn C, Gately L, Gibbs P. Early death after chemotherapy as a quality indicator—is it time to bench the benchmark? JAMA Oncol. 2022;8:1559–60.

Article  PubMed  Google Scholar 

Burgers JA, Damhuis RA. 30-day mortality after the start of systemic anticancer therapy for lung cancer: is it really a useful performance indicator? ERJ Open Res. 2018;4:00030-2018.

Article  PubMed  PubMed Central  Google Scholar 

Vizient Inc. Member-driven healthcare performance improvement. https://www.vizientinc.com/. Accessed July 2023.

Premier Healthcare. https://hcahoustonpremierhealthcare.com/. Accessed July 2023.

Ho G, Wun T, Muffly L, Li Q, Brunson A, Rosenberg AS, et al. Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute-designated cancer centers in California. Cancer. 2018;124:1938–45.

Article  CAS  PubMed  Google Scholar 

Bhatt VR, Shostrom V, Giri S, Gundabolu K, Monirul Islam KM, Appelbaum FR, et al. Early mortality and overall survival of acute myeloid leukemia based on facility type. Am J Hematol. 2017;92:764–71.

Article  PubMed  Google Scholar 

DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, et al. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia. J Clin Oncol. 2021;39:2768–78.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, et al. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematol. 2022;9:e350–60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kadia TM, Reville PK, Borthakur G, Yilmaz M, Kornblau S, Alvarado Y, et al. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2021;8:e552–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kantarjian H, Haddad FG, Jain N, Sasaki K, Short NJ, Loghavi S, et al. Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia. J Hematol Oncol. 2023;16:44.

Article  PubMed  PubMed Central  Google Scholar 

Abramson JS. Anti-CD19 CAR T-cell therapy for B-cell non-Hodgkin lymphoma. Transfus Med Rev. 2020;34:29–33.

Article  PubMed  Google Scholar 

Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380:1726–37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Einsele H, Borghaei H, Orlowski RZ, Subklewe M, Roboz GJ, Zugmaier G, et al. The BiTE (bispecific T-cell engager) platform: development and future potential of a targeted immuno-oncology therapy across tumor types. Cancer. 2020;126:3192–201.

Article  CAS  PubMed  Google Scholar 

van de Donk NWCJ, Usmani SZ, Yong K. CAR T-cell therapy for multiple myeloma: state of the art and prospects. Lancet Haematol. 2021;8:e446–61.

Article  PubMed  Google Scholar 

Gordon MJ, Smith MR, Nastoupil LJ. Follicular lymphoma: the long and winding road leading to your cure? Blood Rev. 2023;57:100992.

Article  PubMed  Google Scholar 

Kantarjian H, O’Brien S, Cortes J, Giles F, Faderl S, Jabbour E, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106:1090–8.

Article  PubMed  Google Scholar 

Kantarjian H, Ravandi F, O’Brien S, Cortes J, Faderl S, Garcia-Manero G, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood. 2010;116:4422–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kantarjian HM, Short NJ, Fathi AT, Marcucci G, Ravandi F, Tallman M, et al. Acute myeloid leukemia: historical perspective and progress in research and therapy over 5 decades. Clin Lymphoma Myeloma Leuk. 2021;21:580–97.

Article  CAS  PubMed  Google Scholar 

Kantarjian H, Kadia T, DiNardo C, Daver N, Borthakur G, Jabbour E, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11:41.

Article  PubMed  PubMed Central  Google Scholar 

Sasaki K, Kadia T, Begna K, DiNardo CD, Borthakur G, Short NJ, et al. Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. Am J Hematol. 2022;97:68–78.

Article  CAS  PubMed  Google Scholar 

Sasaki K, Ravandi F, Kadia T, DiNardo C, Borthakur G, Short N, et al. Prediction of survival with intensive chemotherapy in acute myeloid leukemia. Am J Hematol. 2022;97:865–76.

Article  CAS  PubMed  Google Scholar 

Sasaki K, Ravandi F, DiNardo C, Welch MA, Kadia T, Kantarjian H. Early mortality as a quality indicator in frontline and salvage acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2023. https://doi.org/10.1016/j.clml.2023.08.016.

Kessler RC, Cox BJ, Green JG, Ormel J, McLaughlin KA, Merikangas KR, et al. The effects of latent variables in the development of comorbidity among common mental disorders. Depress Anxiety. 2011;28:29–39.

Article  PubMed  PubMed Central  Google Scholar